$887 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 100 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 77.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SERIES TRUSTput | $193,725,000 | +83.7% | 2,700,000 | +145.5% | 21.84% | +80.4% |
| MYL | Buy | MYLAN N V | $45,956,000 | -5.2% | 1,677,241 | +26.6% | 5.18% | -7.0% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $32,747,000 | -2.3% | 630,000 | +16.7% | 3.69% | -4.1% |
| CELG | New | CELGENE CORP | $29,802,000 | – | 465,000 | +100.0% | 3.36% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $23,452,000 | +8.5% | 2,447,994 | +36.9% | 2.64% | +6.5% |
| AZN | New | ASTRAZENECA PLCsponsored adr | $19,560,000 | – | 515,000 | +100.0% | 2.20% | – |
| PANW | New | PALO ALTO NETWORKS INC | $17,514,000 | – | 24,885 | +100.0% | 1.97% | – |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $16,366,000 | -16.9% | 168,100 | +18.6% | 1.84% | -18.4% |
| ITRN | New | ITURAN LOCATION AND CONTROL | $14,637,000 | – | 122,177 | +100.0% | 1.65% | – |
| BLUE | Buy | BLUEBIRD BIO INC | $13,769,000 | +20.3% | 138,796 | +77.0% | 1.55% | +18.1% |
| ALLT | Buy | ALLOT COMMUNICATIONS LTD | $13,513,000 | +481.0% | 595,764 | +58.3% | 1.52% | +470.4% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $12,716,000 | +3.4% | 116,517 | +53.1% | 1.43% | +1.6% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $12,413,000 | +63.7% | 221,269 | +138.6% | 1.40% | +60.8% |
| PTCT | Buy | PTC THERAPEUTICS INC | $11,858,000 | +20.1% | 345,500 | +64.5% | 1.34% | +18.0% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $10,863,000 | +152.2% | 704,500 | +252.2% | 1.22% | +147.3% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $10,226,000 | -35.1% | 1,232,089 | +7.9% | 1.15% | -36.3% |
| IMMU | Buy | IMMUNOMEDICS INC | $10,082,000 | -30.8% | 706,539 | +1.1% | 1.14% | -32.1% |
| SAGE | Buy | SAGE THERAPEUTICS INC | $9,914,000 | +17.0% | 103,500 | +72.5% | 1.12% | +14.8% |
| AXGT | New | AXOVANT SCIENCES LTD | $8,167,000 | – | 8,200,000 | +100.0% | 0.92% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $7,499,000 | – | 77,000 | +100.0% | 0.84% | – |
| OSMT | New | OSMOTICA PHARMACEUTICALS PLC | $7,147,000 | – | 922,200 | +100.0% | 0.81% | – |
| QURE | Buy | UNIQURE NV | $6,711,000 | +3.7% | 232,849 | +30.9% | 0.76% | +1.7% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $6,034,000 | – | 147,000 | +100.0% | 0.68% | – |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $5,820,000 | – | 370,000 | +100.0% | 0.66% | – |
| GILT | Buy | GILAT SATELLITE NETWORKS LTD | $5,705,000 | +308.1% | 166,663 | +2.0% | 0.64% | +301.9% |
| ARQL | Buy | ARQULE INC | $5,630,000 | -50.4% | 2,032,643 | +1.4% | 0.64% | -51.3% |
| MHK | New | MOHAWK INDS INC | $4,659,000 | – | 10,661 | +100.0% | 0.52% | – |
| EPZM | Buy | EPIZYME INC | $4,617,000 | +9.0% | 749,502 | +87.6% | 0.52% | +7.0% |
| LOGC | New | LOGICBIO THERAPEUTICS INC | $4,343,000 | – | 417,625 | +100.0% | 0.49% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $4,298,000 | – | 290,001 | +100.0% | 0.48% | – |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $4,125,000 | -4.4% | 273,151 | +17.2% | 0.46% | -6.1% |
| CARA | Buy | CARA THERAPEUTICS INC | $3,951,000 | -35.5% | 303,930 | +18.8% | 0.44% | -36.8% |
| SGMO | New | SANGAMO THERAPEUTICS INC | $3,903,000 | – | 340,000 | +100.0% | 0.44% | – |
| STRO | Buy | SUTRO BIOPHARMA INC | $3,679,000 | -10.8% | 407,889 | +48.3% | 0.42% | -12.4% |
| NEOS | Buy | NEOS THERAPEUTICS INC | $3,633,000 | -9.9% | 2,201,697 | +164.7% | 0.41% | -11.7% |
| KRYS | New | KRYSTAL BIOTECH INC | $3,629,000 | – | 174,625 | +100.0% | 0.41% | – |
| ARVN | Buy | ARVINAS INC | $3,483,000 | -14.0% | 271,053 | +12.9% | 0.39% | -15.5% |
| XBI | New | SPDR SERIES TRUSTs&p biotech | $3,228,000 | – | 45,000 | +100.0% | 0.36% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $3,112,000 | – | 67,500 | +100.0% | 0.35% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $3,055,000 | – | 113,437 | +100.0% | 0.34% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $2,836,000 | -43.4% | 449,484 | +18.4% | 0.32% | -44.3% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $2,415,000 | -43.3% | 115,033 | +4.5% | 0.27% | -44.4% |
| SAGE | New | SAGE THERAPEUTICS INCput | $2,347,000 | – | 24,500 | +100.0% | 0.26% | – |
| TBIO | Buy | TRANSLATE BIO INC | $2,321,000 | -16.1% | 309,400 | +11.8% | 0.26% | -17.6% |
| KRNT | New | KORNIT DIGITAL LTD | $2,122,000 | – | 30,342 | +100.0% | 0.24% | – |
| ARYA | New | ARYA SCIENCES ACQUISITION CO | $2,048,000 | – | 200,000 | +100.0% | 0.23% | – |
| ALNA | Buy | ALLENA PHARMACEUTICALS INC | $1,881,000 | -40.7% | 345,199 | +16.9% | 0.21% | -41.8% |
| UROV | Buy | UROVANT SCIENCES LTD | $1,410,000 | -28.4% | 214,030 | +30.5% | 0.16% | -29.6% |
| DOVA | Buy | DOVA PHARMACEUTICALS INC | $1,402,000 | -44.3% | 185,000 | +54.2% | 0.16% | -45.3% |
| CLSD | Buy | CLEARSIDE BIOMEDICAL INC | $1,268,000 | -82.1% | 1,185,124 | +2.6% | 0.14% | -82.5% |
| IDRA | New | IDERA PHARMACEUTICALS INC | $1,234,000 | – | 445,558 | +100.0% | 0.14% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $686,000 | – | 71,159 | +100.0% | 0.08% | – |
| SBPH | New | SPRING BK PHARMACEUTICALS IN | $530,000 | – | 51,015 | +100.0% | 0.06% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $281,000 | – | 70,162 | +100.0% | 0.03% | – |
| CUE | Buy | CUE BIOPHARMA INC | $235,000 | +29.8% | 50,000 | +150.0% | 0.03% | +23.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.